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ABSTRACT: Background: There is an urgent need to
identify individuals at risk of postural instability and gait dif-
ficulties, and the resulting propensity for falls, in Parkinson’s
disease.
Objectives: Given known relationships between posture and
gait and degeneration of the cholinergic pedunculopontine
nucleus,we investigatedwhethermetrics of pedunculopontine
nucleus microstructural integrity hold independent utility for
predicting future postural instability and gait difficulties and
whether they could be combined with other candidate bio-
markers to improve prognostication of these symptoms.
Methods: We used stereotactic mapping of the pedun-
culopontine nucleus and diffusion tensor imaging to extract
baseline pedunculopontine nucleus diffusivity metrics in
147 participants with Parkinson’s disease and 65 controls
enrolled in the Parkinson’s Progression Markers Initiative.
We also recorded known candidate markers of posture
and gait changes: loss of caudate dopamine and CSF
β-amyloid 1-42 levels at baseline; as well as longitudinal
progression motor symptoms over 72-months.
Results: Survival analyses revealed that reduced dopa-
mine in the caudate and increased axial diffusivity in the
pedunculopontine nucleus incurred independent risk of
postural instability and gait difficulties. Binary logistic
regression and receiver operating characteristics analy-
sis in 117 participants with complete follow-up data at
60 months revealed that only pedunculopontine nucleus
microstructure provided more accurate discriminative
ability for predicting future postural instability and gait
difficulties than clinical and demographic variables
alone.
Conclusion: Dopaminergic and cholinergic loss incur
independent risk for future postural instability and gait
difficulties, and pedunculopontine nucleus microstructure
can be used to prognosticate these symptoms from early
Parkinson’s disease stages. © 2020 The Authors.
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Postural instability and gait disturbance (PIGD) and
the resulting increase in falls is associated with a more
pernicious disease course in Parkinson’s disease (PD),
with rapid development of dementia,1 greater disability,2
and early mortality.3 PIGD and falls tend not to respond
well to dopamine-replacement medications, but virtual-
reality training and nondopaminergic pharmacological
interventions have shown early promise.4 However, their
clinical impact will depend on timely and tailored inter-
ventions. As such, there is an urgent need to understand
the neural mechanisms that underpin these symptoms
and to develop the means to identify individuals at risk.
Longitudinal observational studies have revealed that
future postural and gait impairments in PD can be
predicted at very early disease stages using dopamine
transporter (DAT) imaging of the caudate and measure-
ment of cerebrospinal fluid (CSF) β-amyloid 1-42.5,6
Identification of these candidate biomarkers raises the
potential that individuals at risk of PIGD can be identi-
fied even at very early disease stages, thereby enabling
the development of tailored, preventive interventions to
mitigate these symptoms. However, taking lessons from
cognitive biomarker research,7 predicting PIGD with
the level of accuracy necessary for clinical trials will
depend on our ability to provide a multimodal combi-
natorial biomarker that reflects the multiple underlying
pathophysiological pathways of these symptoms.
There is now strong evidence that loss of brainstem
cholinergic neurons, originating in the pedunculopontine
nucleus (PPN), plays a significant role in the development
of PIGD symptoms. Studies consistently report that cho-
linergic PPN lesions in primates cause significant PIGD.8,9
In humans, in vivo cholinergic positron emission tomog-
raphy (PET) imaging reveals that people with PD with a
history of falls—which are more prevalent in people with
PIGD10—have significantly decreased thalamic cholinergic
innervation (a major component of which originates in
the PPN).11 In addition, the now well-recognized link
between PIGD and cognitive decline in PD12 is suggested
to reflect a common underlying pathology of these symp-
toms originating in the cholinergic neurons of the nucleus
basalis of Meynert (nbM).13 Thus, the cholinergic contri-
bution to PIGD progression is likely to be driven directly
by motor pathways that include the PPN and may also
be mediated by cognitive changes following nbM loss.
However, to our knowledge, no studies have been con-
ducted in humans to determine the specific contributions
of these regions to PIGD in PD.
In vivo structural image analysis of the nbM is now
possible via precision, subregional stereotactic mapping
developed from postmortem histology and magnetic
resonance.14 These methods have revealed the spatio-
temporal patterns of nbM atrophy in Alzheimer’s dis-
ease14 and were recently shown to predict the onset of
cognitive decline in early PD.15,16 Currently, however,
no established imaging method to measure the structure
of the PPN exists. Yet such a measure would provide a
critical investigative tool to understand the causes of
PIGD symptoms and to intervene in their development.
Recently, a stereotactic map of the PPN was devel-
oped to improve targeting of the nucleus for deep
brain stimulation surgery for dopamine-unresponsive
PIGD symptoms.17 Although automated segmentation
of gray and white matter in the brainstem using stan-
dard procedures is not accurate, making volumetry of
the PPN technically difficult because of its brainstem
location, it remains possible that metrics of micro-
structural integrity provided by diffusion tensor imag-
ing (DTI) would be informative to further understand
the neuropathology of PIGD symptoms. Indeed, DTI
of the substantia nigra and nbM have revealed micro-
structural changes in these regions that reflect pro-
gression of motor and nonmotor PD symptoms.16,18
In the current study, we combine precision stereotac-
tic mapping of the PPN with DTI to test the hypothesis
that microstructural integrity in this region can predict
future PIGD symptoms in PD. Given previous sugges-
tions that the nbM may be an important structure for
PIGD,13 we will also explore whether the nbM micro-
structure can predict PIGD. Because the PPN micro-
structure, caudate DAT, and CSF β-amyloid 1-42
concentrations reflect different underlying pathologies,
we expect that the PPN microstructure will provide
additive prediction of PIGD symptoms over that pro-
vided by caudate DAT and/or CSF β-amyloid 1-42 con-
centrations. As such, we additionally test the prediction
that there will be utility in combining these candidate
biomarkers to improve prognostication of PIGD in PD.
Methods
Study Design
The Parkinson’s Progressive Marker’s Initiative
(PPMI) is a longitudinal, multicenter study to assess the
progression of clinical features, imaging, and biological
markers in patients living with PD and healthy controls.
It is a public–private partnership funded by the Michael
J. Fox Foundation for Parkinson’s Research and
funding partners, a full list of which can be found
at https://www.ppmi-info.org/about-ppmi/who-we-are/
study-sponsors/.
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To enroll in the study, participants with PD must have
had a diagnosis for 2 years or less at the screening visit
and be at Hoehn and Yahr stages I or II at the baseline
visit. Additional inclusion criteria for the PPMI database
are described in detail in the PPMI study documents
available at http://www.ppmi-info.org/data. For up-to-
date information on the study, visit www.ppmi-info.org.
Participants
Participants selected from the PPMI for the current study
were all those with coregistered T1-weighted and diffusion-
weighted magnetic resonance imaging (MRI) available at
baseline, along with at least baseline Movement Disorder
Society-UPDRS (MDS-UPDRS) scores. There were
147 participants with PD and 65 control participants.
Clinical, Dopamine Imaging, and CSF
Assessments
Following Stebbins and colleagues,19 PIGD, tremor,
rigidity, and bradykinesia symptoms were measured via
the UPDRS. These were recorded longitudinally, with
data available from baseline, 3, 6, 9,12, and then
6 monthly intervals up to 72 months. To determine
whether PPN diffusivity predicts more serious PIGD, a
PIGD endpoint was defined as PIGD UPDRS score > 5.
This threshold was chosen because it required at least
1 of the 5 items to have been scored at least 2, reflecting
symptoms of a frequency or intensity that are sufficient
to cause a modest impact on function. Because of the
instability of PIGD scores in early disease, participants
meeting this threshold within the first year were required
to also have PIGD scores >5 in subsequent years to be
defined as having PIGD. For the same reason, we have
chosen not to classify patients by PIGD or tremor-
dominant “phenotypes.” This threshold identified ~18%
of the sample with more severe PIGD over follow-up.
Endpoints were also defined for tremor, bradykinesia,
and rigidity. We tailored these so that ~18% of the PD
group met the endpoints, thereby ensuring similar
power in statistical tests evaluating risk of each of these
symptom types (described Statistical Analysis). The
UPDRS thresholds that met this condition were as fol-
lows: tremor ≥14, rigidity ≥11, and bradykinesia ≥24.
CSF collection was available in 142 of the PD partici-
pants with DTI and was performed as described in the
PPMI biologics manual (http://www.ppmi-info.org/).
CSF β-amyloid 1-42 concentrations were analyzed at
the University of Pennsylvania according to the
methods in Kang and colleagues.20
All subjects also had DAT imaging at baseline
acquired using I-123 Ioflupane single-photon emission
computed tomography. The images were centrally
reconstructed, attenuation corrected, and caudate and
putaminal binding ratios were calculated with reference
to DAT counts in the occipital lobe via a standardiZed
volume of interest template for extraction of regional
count densities (http://www.indd.org/).
Regions of Interest
PPN
The PPN is the primary area of interest in this study,
and diffusion metrics in this region were accessed via a
mask created using the methods described in ref. 17.
Briefly, postmortem MRI was performed on the brain
of a 66-year-old woman without parkinsonism or cog-
nitive decline. Following autopsy, the brain was fixed,
dehydrated, serially sectioned, and Nissl stained.23
Light and darkfield microscopy was used to enhance
contrast and perform the segmentation of the nuclear
boundaries of the PPN, creating a mask of the entire
PPN region. Following digitization, the images were
3-dimensionally registered with the postmortem MRI,
and the PPN mask transformed to MNI space via trans-
forms generated following normalisation of the post-
mortem MRI to MNI space.24
NbM
Given the previous clinical and animal lesion studies
showing a relationship between the nbM and PIGD deficits,
we also extracted diffusion metrics from a basal forebrain
region of interest (ROI), created as described in ref. 14. In
brief, the map was derived from combined postmortem
MRI and subsequent histological preparation of a brain
specimen of a 56-year-old male who had died without any
evidence of cognitive decline or psychiatric illnesses. Cere-
bral MRI scans were performed in situ. Cholinergic nuclei
were identified and delineated on digital pictures of the sta-
ined brain slices, then manually transferred from the digital
pictures into the corresponding magnetic resonance slices.
Transformation of the delineations from the space of the
dehydrated brain into the space of the in situ brain scan was
performed using a high-dimensional nonlinear registration
between the 2 brain scans25 before final transformation
from in situ space into MNI space using diffeomorphic ana-
tomical registration through exponentiated lie algebra
(DARTEL). The stereotactic cholinergic basal forebrain
map distinguishes different cholinergic subdivisions. In the
current article, we retained the ROI corresponding to
the nbM.
Two additional ROIs were used as controls: a whole
gray matter (GM) mask created from binarized images
of GM segmentations produced as part of the DARTEL
procedure, used to control for more widespread
changes to brain diffusivity. In addition, to control for
the potential contamination of the PPN ROI by nearby
white matter, we drew a circular ROI in the
corticospinal tract (CST), adjacent to the PPN mask,
for use as a nuisance variable in statistical tests.
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MRI Processing
Diffusion-weighted images were preprocessed by the
PPMI study team according the pipeline described in
http://www.ppmi-info.org/wp-content/uploads/2011/12/
DTI-processing-Pipeline3.pdf. This pipeline produces
eigenvalue (λ) maps coregistered to T1 anatomical
images, which we downloaded from the PPMI. The
workflow employed following this is illustrated in
Figure 1. First, to transform MNI-space ROI images
(described in Regions of Interest) to native space,
T1-images were first segmented into separate gray,
white, and CSF tissue compartments for DARTEL ini-
tialization, implemented in SPM12 (https://www.fil.ion.
ucl.ac.uk/spm/software/spm12/). DARTEL performs a
diffeomorphic algorithm for intersubject registration,
producing individual flow field maps (which parameter-
ize the deformation of the images) as well as average
gray and white matter templates. The MNI-space
ICBM152 brain21 was then DARTEL registered to the
template separately, and the resultant flow field was
used to transform the MNI-space ROIs into the average
template space. Finally, the participants’ individual flow
fields were used to inverse transform the warped ROI
images into participant native space. All warps of the
ROI maps used nearest-neighbor interpolation. Each
ROI was visually checked by an expert observer for
alignment with the PPN (author N.J.) and nbM (author
N.J.R.) regions.
In addition, the current gold-standardmethod for locating
the PPN involves using atlas-based coordinates, described
by Zrinzo and colleagues.22 To confirm our methods, we
tested whether the transformed PPN ROI masks overlapped
with the coordinates provided in Zrinzo and colleagues,22 in
a smaller selection of 20 images. Figure 2 illustrates this
check, showing a representative image from a single partici-
pant with the PPNmask overlaid along with the atlas-based
coordinates of the rostral pole of the PPN.
Finally, mean eigenvalues from the ROIs were
extracted from each of the 3 eigenvalue images, and
mean, axial (along the principal axis), and radial (per-
pendicular to the principal axis) diffusivity (mD, aD, rD,
respectively) were calculated according to the following:
mD = (λ1 + λ2 + λ3)/ 3; aD = λ1; rD = (λ2 + λ3)/ 2. Please
note that we have not utilized the fractional anisotropy
maps available in the PPMI for the current analysis. We
avoided this because changes in fractional anisotropy are
extremely difficult to interpret in GM (degeneration of
FIG. 1. Preprocessing workflow. T1-images and the MNI space ICBM152 brain14 were DARTEL registered. MNI-space ROI masks were transformed
into average template space and then inverse transformed into native space. PPN, pedunculopontine nucleus; ROI, region of interest. [Color figure can
be viewed at wileyonlinelibrary.com]
FIG. 2. Atlas-based localization of the pedunculopontine nucleus.
Localization of the pedunculopontine nucleus using the current auto-
matic method (voxels are labeled in white following procedure outlined
in Fig. 1). The voxels identified as belonging to the pedunculopontine
nucleus were then confirmed using the manual atlas-based method
described in Zrinzo and colleagues22 (red point represents the rostral
pole of the atlas coordinates provided in that article). AC, anterior cingu-
late; PC, posterior cingulate. [Color figure can be viewed at
wileyonlinelibrary.com]
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neurons oriented in different directions would cause a
paradoxical increase in fractional anisotropy, whereas
degeneration of neurons oriented in the same direction
would have the opposite effect), and this may be particu-
larly true in a region such as the PPN that is expected to
be heavily myelinated.
Statistical Analysis
Statistical analyses were conducted in SPSS Statistics
version 22 (IBM, Armonk, NY) and R (http://www.R-
project.org/; R Foundation for Statistical Computing,
Vienna, Austria).
Baseline Demographics, Clinical Scores,
Diffusivity, DAT, and CSF Measures
Analyses of variance and post hoc Tukey tests were
used to compare demographics, clinical measures, diffu-
sivity metrics, mean caudate DAT, and CSF β-amyloid
1-42 metrics between the controls and PD participants
who did/did not develop more severe PIGD. Subsequent
univariate tests were conducted for diffusivity metrics
that showed between-group differences, controlling for
age, UPDRS part III scores and whole GM and CST
diffusivity. Note that diffusivity metrics were matched
in each analysis, for example, comparisons/correlations
involving PPN aD controlled for whole brain aD and
CST aD.
Survival Analysis
Cox proportional hazards regression analyses were
used to test the hypothesis that development of more
severe PIGD can be predicted by PPN microstructure
measured at the time of PD diagnosis. None of the
variables included violated collinearity assumptions.
Time to severe PIGD was calculated as the number of
months since study enrolment until the PIGD thresh-
old (PIGD >5) was reached. One participant already
meeting this threshold at baseline was excluded from
this analysis. The prediction of severe tremor, rigidity,
and bradykinesia were also evaluated in separate Cox
regressions.
Control variables considered for inclusion in the anal-
ysis were age, Montreal Cognitive Assessment, UPDRS
part III, baseline PIGD, and sex. This clinical and
demographics only model was run as a first step, and
all predictors surviving P < 0.2 were retained for the
full model, with sex and Montreal Cognitive Assess-
ment not meeting this criterion. Diffusivity metrics from
each ROI were then added to the model separately
(with whole GM and CST diffusivity added as addi-
tional control variables).
Caudate DAT and CSF β-amyloid 1-42 concentra-
tions were subsequently added to the clinical, demo-
graphics, and diffusivity models to determine their
shared and/or unique predictive relationships with dif-
fusivity metrics for PIGD.
Binary Logistic Regression and ROC Analysis
In a smaller sample of participants with full data
available at the 60-month follow-up visit (N = 117),
binary logistic regression was used to model the predic-
tive relationships between PIGD and candidate markers
along with clinical and demographic variables. Using
the pROC26 package in R, ROC curves were con-
structed from the predicted values from a demo-
graphics and clinical characteristics-only model and
from models including candidate markers together
or in isolation. Areas under the curves (AUC) were
compared with the DeLong method,27 with the pre-
diction that inclusion of biomarkers would provide
more accurate discriminative ability for predicting
PIGD than the clinical and demographic-only
model.
Correction for Multiple Comparisons
All analyses are presented with uncorrected P values,
and those surviving false discovery rate correction for
number of diffusivity metrics and number of ROIs
included in the analysis are noted in the text.
Results
Clinical, Demographic, and Diffusivity
Characteristics at Baseline in Controls, People
with PD Who Develop PIGD During Follow-Up
Visits, and People with PD Who Do Not
Develop PIGD at Follow-Up
A total of 27 (18.4%) participants with PD devel-
oped severe PIGD during the 72-month follow-up
period. One-way analysis of variance and post hoc
Tukey tests revealed that the PD participants who
developed PIGD during the follow-up period were
older and had worse UPDRS part III scores at base-
line than those who did not develop PIGD. This
group was also found to have greater aD in the
PPN when compared with both controls and partici-
pants with PD who did not develop PIGD (statistics
reported in Table 1).
The latter finding survived false discovery rate correc-
tion for 2 (ROI: nbM and PPN) × 3 (diffusivity metrics:
aD, mD, and rD) multiple comparisons, and univariate
analyses revealed that PPN aD was significantly greater
in the PD participants who did develop PIGD (com-
pared with those who did not) even after controlling
for age, sex, UPDRS part III scores, Montreal Cognitive
Assessment scores, and CST aD and whole GM aD
(F = 10.57, P = 0.001).
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More severe tremor, rigidity, and bradykinesia devel-
oped in 28, 26, and 31 patients with PD, respectively.
There was some overlap between these groups (8, 14,
and 15 patients with more severe tremor, rigidity, and
bradykinesia also had more severe PIGD). However,
diffusivity metrics were not different in those develop-
ing these symptoms versus those who did not
(T < 1.62, P > 0.10).
Do Diffusivity Characteristics Incur Risk
for PIGD Independently from Clinical
and Demographic Markers for PIGD:
Survival Analysis
Clinical and demographic variables (age, baseline
PIGD, and total UPDRS part III scores) were entered
into Cox regression models along with diffusivity met-
rics in the nbM and PPN. Whole GM and CST diffusiv-
ity were also entered as control regions. NB, the
3 diffusivity metrics (aD, mD, and rD) extracted from
the 2 ROIs (nbM and PPN) were entered into separate
models, and therefore results are corrected for 3 × 2
multiple comparisons.
PPN aD was the only metric to be associated with
significant independent risk of developing PIGD (PPN
aD: Wald = 9.32, P = 0.002 [survives false discovery
rate correction for multiple comparisons]). For the
nbM and all other diffusivity metrics, Wald <0.90 and
P > 0.35. To determine the specificity of PPN aD for
predicting PIGD, we repeated the survival analysis to
predict tremor, rigidity, and bradykinesia. None of
these were found to be predicted by PPN aD (Wald
<1.81, P > 0.18).
Do Diffusivity Characteristics Incur Risk
for PIGD Independently from Clinical,
Demographic, and Other Candidate Markers
for PIGD: Survival Analysis
Given the previous results, the analyses that follow
were not performed for diffusivity metrics in the nbM.
Caudate DAT, but not putamen DAT, also predicted
future PIGD (caudate: Wald = 7.63, P = 0.006; puta-
men: Wald = 0.72, P = 0.40). With PPN aD and cau-
date DAT entered together (as well as CST and whole
GM aD), PPN aD (Wald = 6.60, P = 0.01) and caudate
DAT (Wald = 3.11, P = 0.05) explained the significant
independent risk of PIGD.
CSF β-amyloid 1-42 did not reach significance for
predicting the risk of PIGD in a model that did not
include caudate DAT or PPN aD (Wald = 2.62,
P = 0.11), and both caudate DAT (Wald = 4.75,
P = 0.03) and PPN diffusivity (Wald = 5.81, P = 0.01)
continued to predict PIGD when entered with CSF
β-amyloid 1-42.
Does PPN Diffusivity and/or Other Candidate
Markers of PIGD Improve Discriminative Ability
for Predicting PIGD over Demographic and
Clinical Variables: Binary Logistic Regression
In a sample of participants with follow-up data avail-
able at 60 months (N = 117), a binary logistic
TABLE 1. Demographics, clinical characteristics, and diffusivity metrics
Participants with PD and PIGD <6 During
Follow-Up (N = 120, Female = 46)
Participants with PD and PIGD ≥6 During
Follow-Up (N = 27, Female = 8)
Controls (N = 65,
Female = 22)
Mean SD Mean SD Mean SD
Age, y 60.49 9.32 65.17 9.05 60.51 10.66
Education, y 15.34 3.12 14.74 2.75 15.23 3.06
MDS-UPDRS part III 19.67 8.10 25.19 11.26 0.57 1.31
MoCA 27.62 2.07 27.15 2.29 28.17 1.14
Caudate DAT 1.94 0.49 1.62 0.60 2.71 0.43
CSF β-amyloid 1-42 (pg/mL) 865.70 324.57 781.31 316.87 961.42 467.41
PPN aD 1.21 0.094 1.28 0.10 1.23 0.094
PPN mD 0.69 0.05 0.71 0.06 0.70 0.06
PPN rD 0.41 0.06 0.41 0.06 0.44 0.07
nbM aD 1.28 0.13 1.29 0.08 1.25 0.13
nbM mD 1.01 0.13 1.03 0.09 0.99 0.11
nbM rD 0.87 0.14 0.90 0.10 0.86 0.11
Caudal SN aD 1.05 0.11 1.12 0.11 1.03 0.10
Caudal SN mD 0.74 0.10 0.77 0.08 0.72 0.10
Caudal SN rD 0.58 0.09 0.60 0.07 0.56 0.11
Note: Bold values indicate significantly different from PD patients who did not develop PIGD at P < 0.05 corrected.
PD, Parkinson’s disease; PIGD, postural instability and gait difficulties; SD, standard deviation; UPDRS, Unified Parkinson’s Disease Rating Scale; MoCA, Mon-
treal Cognitive Assessment; DAT, dopamine transporter; CSF, cerebrospinal fluid; PPN, pedunculopontine nucleus; aD, aD, axial diffusivity; mD, mean diffusivity;
rD, radial diffusivity; nbM, nucleus basalis of Meynert; SN, substantia nigra; MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s disease Rating Scale.
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regression including demographic and clinical variables,
as well as both PPN aD and caudate DAT confirmed
that PPN aD independently predicted severe PIGD
(Wald = 6.93, P = 0.008), whereas caudate DAT mar-
ginally missed significance (Wald = 3.53, P = 0.06). The
AUC for a ROC curve computed from predicted values
of a binary logistic regression that included only demo-
graphic and clinical variables was 0.74 (95% confi-
dence interval, 0.64–0.87). Improvements to this
provided by PPN aD (AUC, 0.82; 95% confidence
interval, 0.72–0.91) were significant (z = 1.8, P = 0.03;
Fig. 3). The addition of the caudate DAT to the demo-
graphic and clinical-only model (AUC: 0.78, CI: 0.66 –
0.89) was not significant (z < 0.88, P > 0.19), and the
model that included both the PPN aD and caudate
DAT (AUC, 0.82; 95% confidence interval, 0.72–0.92)
was not significantly better than the model including
demographic and clinical variables and PPN aD
(z = 0.48, P = 0.68).
Discussion
Our study shows that microstructural changes in the
PPN are associated with an increased risk for the devel-
opment of PIGD symptoms in PD and have discrimina-
tive ability for predicting PIGD within 5 years, even at
very early disease stages. This finding is specific to the
symptoms of PIGD (development of significant tremor,
rigidity, and bradykinesia symptoms were unrelated to
PPN diffusivity) and was specific to the PPN (micro-
structural changes in the nbM did not incur risk for
PIGD symptoms). The latter finding implies that degen-
eration in the PPN and its relationship with future
PIGD does not reflect a general PD-related decline in
cholinergic subcortical nuclei and supports the sugges-
tion that pathology of the PPN can cause PIGD in
PD. This raises the potential that measures of PPN
microstructure could be used to stratify patients to
enable tailored and preventive interventions for gait
and balance deficits and for future clinical trials.
The anatomical and functional specificity of this find-
ing for the PPN and PIGD, respectively, is consistent with
our current understanding of this region’s role in normal
walking and balance. In animal models, PPN lesions are
sufficient to induce gait deficits, and stimulation of the
PPN results in locomotion.8,9 Depth recordings from the
PPN in humans reveal modulated single-unit firing during
imagined walking28 and enhanced α-band oscillations
during stepping in place.29 Lau and colleagues28 provide
evidence that the PPN influences gait in ways that extend
beyond “pattern generation,” including motor planning
and adaptation. The methods reported in the current arti-
cle will enable further investigation of the role of the
PPN in these skills.
The PPN is a neurochemically heterogeneous structure,
containing gamma aminobutyric acid (GABA)ergic, gluta-
matergic, and cholinergic populations.30 The cholinergic
neurons of the PPN seem to be particularly relevant for
PIGD and falls as demonstrated by the gait deficits
FIG. 3. Receiver operating characteristic curves of predictive models for postural instability and gait disturbance. Receiver operating characteristic
curve for a demographics and clinical characteristics-only model is shown in pink. The addition of PPN aD to the demographics and clinical character-
istics model is shown in blue. aD, axial diffusivity; PPN, pedunculopontine nucleus. [Color figure can be viewed at wileyonlinelibrary.com]
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produced by targeted cholinergic lesions of the PPN in pri-
mates and rodents.8 Positron emission tomography with
cholinergic ligands and pathological data has shown rela-
tionships between PPN-thalamic cholinergic innervation
and PIGD and falls in PD.11 Although the current findings
make no distinction between neurochemical subpopula-
tions of PPN neurons, taken with the previous findings,
we can speculate that PPN aD reflects, at least in part,
degeneration of PPN-thalamic cholinergic projections.
As expected, given previous literature,5 we found that
the risk of PIGD was increased by low caudate DAT at
baseline. This relationship was independent from the
relationship between PPN aD and future PIGD, imply-
ing there are distinct dopaminergic and cholinergic con-
tributions to the risk of developing these symptoms.
There is a known link between PIGDs—specifically
freezing of gait—and frontal executive functions,31 and
the dependence of these on caudate dopamine is well
documented. It is reasonable therefore to speculate that
the link between caudate dopamine depletion and PIGD
is mediated by impaired executive function. Similarly, a
previous study using DTI with tractography revealed
that freezing of gait was associated with reduced con-
nectivity between the PPN and the frontal cortex, which
was in turn associated with impaired executive func-
tion.32 As such, combining the methods reported here
to study these links could reveal the multiple patholo-
gies that underpin the failure of the motor and/or non-
motor networks to support posture and gait in PD.
In follow-up analyses, only PPN aD significantly
increased accuracy of a predictive model for PIGD
beyond clinical and demographic variables alone. These
results indicate that although there is a clear relation-
ship between dopamine deficiency and PIGD,5 it may
not discriminate between people who do/do not
develop these symptoms. Conversely, cholinergic loss
develops more heterogeneously in PD, and the current
findings indicate that this variability provides greater
predictive utility for the symptoms that are underpinned
by this loss.
The corticopetal cholinergic system originating in the
nbM has been linked to gait speed and falls,11,33 but
the risk of PIGD was not predicted by nbM diffusivity
in the current report. It has been suggested that gait
changes and increased falls risk follow cognitive deteri-
oration, particularly in executive function and
attention,34 and that degeneration in the nbM is the
principal underlying factor.13 We are currently investi-
gating whether datasets with more fine-grained cogni-
tive, gait, and postural measures (http://bam-ncl.co.uk/
our-work/studies/icicle-gait/) than provided by the
PPMI are informative for the role of the nbM in these
abilities.
Finally, we did not observe a relationship between
CSF β-amyloid 1-42 concentrations at baseline and risk
of PIGD. Yet, previous data has consistently reported a
relationship between PIGD severity and CSF β-amyloid
levels,5,6 as well as neocortical β-amyloid deposition
measured with PET.35 It is possible that the relationship
between CSF β-amyloid 1-42 concentrations and PIGD
symptoms is more readily detected using methods that
characterize PIGD severity using more fine-grained,
continuous measures rather than when PIGD is
expressed as a dichotomous variable as required by sur-
vival and binary regression analyses. As such, the lack
of a predictive relationship reported here between CSF
β-amyloid 1-42 concentrations and UPDRS PIGD >5
should be viewed as a limitation of these methods
rather than evidence that a relationship does not exist.
Some caveats to the current study must be acknowl-
edged. First, volumetry of the PPN is difficult because
of the requirement to accurately segment white matter
and GM in this region. As such, we have not corrected
for partial volume effects. However, our aim was to
provide a measure of structural change in the region
that may have utility for understanding and predicting
PIGD in PD. Therefore, whether our prognostic marker
reflects micro- and/or macro-structural changes is not a
focus of the current article. That said, the application
of more accurate segmentation procedures for
brainstem structures are warranted. Similarly, the seem-
ing specificity of the marker for PPN aD, rather than
mD or rD, is currently open to interpretation. The cur-
rent analysis is not able to determine the specific neuro-
degenerative process that leads to increased
aD. However, we are continuing to investigate the rela-
tionship between the PPN and PIGD using alternative
DTI metrics36 that will enable us to address these addi-
tional questions.
In addition, we defined PIGD >5 as the end point for
our predictive analyses as it allowed us to distinguish
individuals who are beginning to experience functional
limitation attributable to at least 1 PIGD marker.
However, it is not clear from the current study
whether this is the most sensitive end point to use. It is
also not clear whether there is a linear relationship
between PPN degeneration and the emergence of
PIGD symptoms. Future work could aim to explore
these relationships to determine the point at which
PPN degeneration becomes risky for developing PIGD
as well as whether longitudinal progression of PPN
degeneration is more informative than cross-sectional
baseline data for predicting PIGD. Finally, it must also
be noted that PIGDs are overrepresented in atypical
parkinsonian disorders,37 and it is therefore possible
that patients developing PIGD in the current sample
may later be diagnosed with atypical parkinsonian
disorders.
In conclusion, stereotactic mapping alongside DTI
of the PPN can be used to prognosticate PIGD in
PD. The relationship between baseline PPN micro-
structure and future PIGD was independent from the
8 Movement Disorders, 2020
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relationship between caudate dopamine deficiency
and future PIGD, implying that there are distinct
dopaminergic and cholinergic contributions to the
risk of developing these symptoms. It is now neces-
sary to further investigate how measures of PPN and
dopaminergic integrity could be combined in algo-
rithms to predict the onset of particular components,
or complications, of PIGD, such as freezing of gait or
falls.
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